{"Clinical Trial ID": "NCT00618826", "Intervention": ["INTERVENTION 1:", "Treatment", "- Paclitaxel / Gemcitabine"], "Eligibility": ["Incorporation criteria:", "The patient should be 18 years of age or older with histologically confirmed breast cancer and clinical evidence of metastatic disease.", "The X-rays, scans or physical examinations used to assess a measurable disease must be performed within 28 days prior to registration. X-rays, scans or physical examinations to assess a non-measurable disease must be performed within 42 days prior to registration.", "Patients must meet the following requirements for prior and concomitant chemotherapy: Patients must not have received prior chemotherapy for metastatic breast cancer. Patients may have received adjuvant/neoadjuvant chemotherapy for a total of 3 previous treatments.", "A prior treatment with paclitaxel or docetaxel is allowed in the adjuvant or neoadjuvant setting if administered > 6 months prior to registration.", "Patients should be more than 14 days late between the conclusion of any radiation and the onset of gemcitabine, provided that the acute effects of radiation therapy have been eliminated.", "Patients may have received any number of exogenous hormonal treatments and/or trastuzumab in the adjuvant, neoadjuvant or metastatic setting.", "Patients may receive concomitant bisphosphonate therapy for bone metastases.", "\u2022 Patients should have recovered from any previous surgery; two weeks should have elapsed from any minor surgery and four weeks from any major surgery.", "Patients should have sufficient bone marrow storage, as shown by the following data: ANC > 1500/mcL, platelets > 100,000/mcL and hemoglobin > 9.0 gm/dL. These results should be obtained within 28 days prior to registration.", "Patients should have serum creatinine < 1.5 mg/dL within 28 days of registration.", "Urine Proteins: creatinine ratio 1.0 to screening.", "Patients should have adequate liver function.", "Patients should have a Zubrod performance of 0-1.", "- Exclusion criteria:", "Patients should not have tumours that carry gene HER-2 amplifications as determined by (i) in situ fluorescence hybridization (FISH) or (ii) overexpression of the HER-2 3+ immunohistochemistry protein; or may have tumours that carry HER=2 gene amplification and have had disease progression during trastuzumab. Patients who have already been treated with trastuzumab should be out of treatment at least 28 days prior to registration.", "Patients should not have CNS metastases, leptomenesis or lymphatic pulmonary metastases.", "Patients should not have received previous treatment with gemcitabine or bevacizumab.", "The patient should not undergo major surgery, open biopsy or traumatic lesions within 28 days prior to the start of treatment, in anticipation of the need for major surgery during the study.", "Patients should not have received radiation at more than 50% of the bone bearing the marrow.", "Patients should not have a history of significant symptomatic heart disease or left ventricular ejection fraction (LVEF) < 50% of the lower institutional limit of normal (NII).", "Patients with uncontrolled hypertension are NOT eligible (BP>150/100).", "Patients should not have clinically significant pre-existing motor neuropathy or sensory neuropathy (grade 2 or higher depending on CTCAE version 3.0), except for cancer abnormalities.", "Patients known to be HIV positive.", "Men and women with reproductive potential must agree to use an effective contraceptive method.", "No other prior malignancy is permitted, except in the following cases: skin cancer of properly treated basal or squamous cells, cervical cancer in situ, stage I or stage II cancer properly treated, whose patient has not been reached for 5 years.", "Patients with unstable agina, major peripheral vascular disease, a history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscesses in the last 6 months should be excluded."], "Results": ["Performance measures:", "- Survivors without progression", "Time between entry into the study and progression or death of the disease", "Duration: maximum 50 months", "Results 1:", "Title of arm/group: Treatment", "Description of the arm/group: Paclitaxel / Gemcitabine", "Total number of participants analysed: 13", "Median (95% confidence interval)", "Unit of measure: months 43 (7 to 45)"], "Adverse Events": ["Undesirable Events 1:", "Total: 10/14 (71.43 per cent)", "Hemoglobin 2/14 (14.29 per cent)", "- Lymphopenia 1/14 (7.14 per cent)", "1/14 (7.14 per cent)", "Hypertension 2/14 (14.29 per cent)", "Hypotension 1/14 (7.14 per cent)", "Constipation 1/14 (7.14 per cent)", "Diarrhoea 1/14 (7.14 per cent)", "- Stomach burns/dyspepsia 1/14 (7.14%)", "Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)", "1/14 (7.14 per cent)"]}